Those are two very different questions.
As I said a few minutes ago, if we want to reassure Canadians that our system is working and is fair, we must continue to work with other countries to prevent companies from finding ways around what we want to accomplish.
We are continuing to work with the OECD to find ways of improving our system. Each year, we consider measures that we can take to that end. In budget 2020, we are currently considering the measures that will improve the way in which the system works.
There is nothing I can say today, but there is a lot to do.
To answer your second question, as we have said, a universal pharmacare program is very important. We have to consider how we can work with the provinces to come up with an approach that will work well in the future.
That is why we began with what we can do together. The work on expensive drugs for rare diseases is a good example of that. We will continue to have discussions and to work with the provinces to reduce the cost of the drugs and to ensure that everyone in the country has good access to them.
Those two objectives are very important and we are currently working to achieve them with our colleagues and, of course, with those in the provinces.